Stay updated on MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Sign up to get notified when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.

Latest updates to the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe page’s revision label updates from “v3.5.2” to “v3.5.3,” reflecting a change in the site’s display/versioning rather than the underlying study record.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision metadata updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision: v3.4.3 was added to the history log, and Revision: v3.4.2 was removed.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision: v3.4.2 has been added and Revision: v3.4.1 has been removed.SummaryDifference0.1%

- Check81 days agoChange DetectedThis is a minor metadata update: the revisions history shows Revision: v3.4.1, replacing v3.4.0, with no changes to study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.